MetLife MET underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 5 | 1 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 3 | 0 | 0 | 0 |
2M Ago | 1 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 2 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $93.57, a high estimate of $99.00, and a low estimate of $88.00. Observing a 2.26% increase, the current average has risen from the previous average price target of $91.50.
Exploring Analyst Ratings: An In-Depth Overview
The perception of MetLife by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Jack Matten | BMO Capital | Announces | Market Perform | $97.00 | - |
Elyse Greenspan | Wells Fargo | Lowers | Overweight | $92.00 | $93.00 |
Jimmy Bhullar | JP Morgan | Raises | Overweight | $88.00 | $86.00 |
Alex Scott | Barclays | Raises | Overweight | $96.00 | $90.00 |
Daniel Bergman | TD Cowen | Raises | Buy | $99.00 | $97.00 |
Elyse Greenspan | Wells Fargo | Raises | Overweight | $93.00 | $92.00 |
Alex Scott | Barclays | Lowers | Overweight | $90.00 | $91.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MetLife. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MetLife compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of MetLife's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of MetLife's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on MetLife analyst ratings.
About MetLife
MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.
Unraveling the Financial Story of MetLife
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: MetLife's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 16.6%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: MetLife's net margin is impressive, surpassing industry averages. With a net margin of 6.98%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): MetLife's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.39% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.18%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 0.61, MetLife faces challenges in effectively managing its debt levels, indicating potential financial strain.
What Are Analyst Ratings?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.